Jane Street Group LLC lowered its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 70.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 23,613 shares of the biopharmaceutical company's stock after selling 56,878 shares during the quarter. Jane Street Group LLC's holdings in Vanda Pharmaceuticals were worth $113,000 as of its most recent SEC filing.
A number of other institutional investors also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP lifted its stake in Vanda Pharmaceuticals by 10.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,488,519 shares of the biopharmaceutical company's stock worth $11,920,000 after acquiring an additional 227,428 shares during the last quarter. Geode Capital Management LLC lifted its stake in Vanda Pharmaceuticals by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 1,450,310 shares of the biopharmaceutical company's stock worth $6,949,000 after acquiring an additional 24,483 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Vanda Pharmaceuticals by 4.9% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 819,382 shares of the biopharmaceutical company's stock worth $3,925,000 after acquiring an additional 38,449 shares during the last quarter. Federated Hermes Inc. lifted its stake in Vanda Pharmaceuticals by 1.4% in the fourth quarter. Federated Hermes Inc. now owns 726,619 shares of the biopharmaceutical company's stock worth $3,481,000 after acquiring an additional 9,840 shares during the last quarter. Finally, Northern Trust Corp lifted its stake in Vanda Pharmaceuticals by 1.3% in the fourth quarter. Northern Trust Corp now owns 507,442 shares of the biopharmaceutical company's stock worth $2,431,000 after acquiring an additional 6,283 shares during the last quarter. Hedge funds and other institutional investors own 88.14% of the company's stock.
Insider Activity at Vanda Pharmaceuticals
In other Vanda Pharmaceuticals news, CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of Vanda Pharmaceuticals stock in a transaction that occurred on Wednesday, May 21st. The stock was purchased at an average price of $4.40 per share, for a total transaction of $44,000.00. Following the transaction, the chief executive officer now directly owns 2,325,731 shares in the company, valued at $10,233,216.40. This trade represents a 0.43% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 10.00% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on the stock. Cantor Fitzgerald reiterated an "overweight" rating and issued a $13.00 price target on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 14th. HC Wainwright reiterated a "buy" rating and issued a $20.00 price target on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 7th.
Read Our Latest Stock Report on VNDA
Vanda Pharmaceuticals Trading Up 5.0%
Shares of NASDAQ:VNDA opened at $4.61 on Friday. The company has a market capitalization of $271.69 million, a PE ratio of -14.41 and a beta of 0.66. Vanda Pharmaceuticals Inc. has a twelve month low of $3.81 and a twelve month high of $6.75. The firm has a 50 day simple moving average of $4.29 and a 200-day simple moving average of $4.57.
Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.05. The business had revenue of $50.04 million during the quarter, compared to the consensus estimate of $45.13 million. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. As a group, equities research analysts predict that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current fiscal year.
Vanda Pharmaceuticals Company Profile
(
Free Report)
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Vanda Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vanda Pharmaceuticals wasn't on the list.
While Vanda Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
